UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ARAV Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36361 Aravive, Inc. (Exact name of Registrant as specified in its Charter) Delaware 2834 26-4106690 (State or Other Jurisdiction of I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36361 Aravive, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organizati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36361 Aravive, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 26-4106690 (State or Other Jurisdiction of Incorpo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------- ...

Financial Performance - Total revenue for 2018 was $1.4 million, a decrease of 97% from $40 million in 2017[363]. - The company generated grant revenue of $1.4 million for the year ended December 31, 2018, and recognized contract revenue of $40.0 million for the year ended December 31, 2017[337]. - Net loss for 2018 was $76.3 million, a reduction of 10% from a net loss of $84.9 million in 2017[363]. - Net cash used in operating activities was $29.3 million in 2018, a decrease from $116.3 million in 2017[376]. - Interest income increased to approximately $1 million in 2018 from $0.8 million in 2017, primarily due to rising interest rates[368]. - Interest expense increased to $2.4 million in 2018 from $0.5 million in 2017, mainly due to lease obligations[369]. - Net cash provided by financing activities was $2.0 million in 2018, down from $3.0 million in 2017[378]. Expenses - Research and development expenses decreased by $83.5 million, or 88%, to $11.1 million in 2018 from $94.6 million in 2017[366]. - General and administrative expenses decreased by $2.5 million, or 8%, to $27.4 million in 2018 from $29.9 million in 2017[367]. - Stock-based compensation expense for the years ended December 31, 2018, and 2017 was $16.1 million and $13.3 million, respectively[353]. - The company anticipates a decrease in general and administrative expenses in future periods due to reduced headcount and infrastructure[340]. Cash Position - Cash and cash equivalents as of December 31, 2018, were $57 million, including $5.3 million acquired from the merger with Private Aravive[372]. - As of December 31, 2018, the company had cash and cash equivalents of approximately $57.0 million, sufficient to sustain operations for at least the next 12 months[378]. Merger and Acquisition - Following the merger, the company became a clinical-stage biotechnology company focused on developing therapies for advanced solid tumors and hematologic malignancies[336]. - The merger was accounted for as an asset acquisition, with the fair value primarily concentrated in in-process research and development[334]. - The merger with Private Aravive resulted in a significant write-off of in-process research and development of $38.3 million[366]. - Approximately 11,182,025 shares of common stock were outstanding immediately following the merger, with about 5,141,915 shares owned by former Private Aravive stockholders[333]. Future Outlook - Future revenue may be generated from product sales, license fees, milestones, and royalties from strategic collaborations[339]. - The company anticipates needing additional financing to advance its clinical development programs[373]. - The company will need to obtain additional financing to advance its clinical development program and fund operations for the foreseeable future[378]. Compliance and Reporting - The company opted out of the extended transition period under the JOBS Act, committing to comply with new or revised accounting standards as they are adopted[380]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[381]. - The company has not engaged in any off-balance sheet arrangements since its inception[379]. Deficit and Working Capital - As of December 31, 2018, the company had an accumulated deficit of approximately $450.6 million and working capital of $56.1 million[337].